[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy-outcomes":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,50,96,120,147,174,198,227,254,278,304,324,357,380,405,436],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100644157","mms-ifa-and-mmsifa-supplementation-in-pregnant-women-100644157",false,"NCT07665957","MMS, IFA, and MMS+IFA Supplementation in Pregnant Women","Comparative Effectiveness of Multiple Micronutrient Supplementation (MMS), Iron-Folic Acid (IFA), and Combined MMS+IFA on Maternal Hemoglobin Levels and Neonatal Outcomes Among Pregnant Women: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Gestational age ≤20 weeks at enrollment\n* Singleton pregnancy\n* Hemoglobin concentration ≥10 g\u002FdL at baseline\n* Willing and able to provide informed consent\n* Willing to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\n* Severe anemia requiring injectable treatment (hemoglobin \\\u003C7 g\u002FdL)\n* Pre-existing diabetes mellitus\n* Pre-existing hypertension\n* Renal disease\n* Current therapeutic iron or micronutrient supplementation beyond routine antenatal supplementation\n* Known fetal congenital anomalies\n* Any medical condition that, in the opinion of the investigator, would interfere with study participation or outcome assessment",true,"FEMALE","18 Years",{"count":20,"type":21},402,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to compare the effectiveness of Multiple Micronutrient Supplementation (MMS), Iron-Folic Acid (IFA) supplementation, and combined MMS+IFA supplementation among pregnant women. Maternal anemia and micronutrient deficiencies are common during pregnancy and can adversely affect both maternal and neonatal health outcomes.\n\nA total of 402 pregnant women with gestational age of 20 weeks or less will be randomly assigned to receive MMS, IFA, or combined MMS+IFA supplementation. Participants will be followed throughout pregnancy until delivery. Maternal hemoglobin levels, maternal compliance with supplementation, and neonatal outcomes including birth weight, preterm birth, APGAR scores, and congenital anomalies will be assessed.\n\nThe findings of this study will provide evidence to guide antenatal nutrition policies and practices in Pakistan.",[27,28,29,30],"Maternal Anemia","Micronutrient Deficiency","Pregnancy Outcomes","Maternal Nutrition",[32,33,34,35,36,27,37,30],"Multiple Micronutrient Supplementation","MMS","Iron Folic Acid","IFA","Pregnancy","Maternal Hemoglobin","NOT_YET_RECRUITING","2026-06-27",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":21},"2026-06-25",{"date":46,"type":21},"2027-01-25",{"name":48,"class":49},"Sindh Institute of Child Health and Neonatology","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100582284","placental-imaging-techniques-100582284","NCT06861309","Placental Imaging Techniques","Evaluation of Innovative Placental Imaging Techniques in Fetal Growth Restriction","Inclusion Criteria:\n\n* Normal-Fetal-Weight Pregnancies Arm: Patient at least 18 to 45 years of age at screening\n* Normal-Fetal-Weight Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders or growth abnormalities\n* Normal-Fetal-Weight Pregnancies Arm: Low-risk aneuploidy screening, if performed\n* Normal-Fetal-Weight Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n* Normal-Fetal-Weight Pregnancies Arm: Anatomical survey has been performed\n* Normal-Fetal-Weight Pregnancies Arm: Pregnancy without current fetal growth restriction (FGR) diagnosis\n* Normal-Fetal-Weight Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Patient at least 18 to 45 years of age at screening\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Low-risk aneuploidy screening, if performed\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Anatomical survey has been performed\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Pregnancy diagnosed with fetal growth restriction (FGR) by estimated fetal weight \\\u003C10th centile or abdominal circumference measurements \\\u003C10th centile\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject\n\nExclusion Criteria:\n\n* Normal-Fetal-Weight Pregnancies Arm: Multiple gestations\n* Normal-Fetal-Weight Pregnancies Arm: Known fetal anomaly affecting biometric measurements\n* Normal-Fetal-Weight Pregnancies Arm: Suspected fetal genetic disorder(s)\n* Normal-Fetal-Weight Pregnancies Arm: Suspected fetal infection(s)\n* Normal-Fetal-Weight Pregnancies Arm: Non-English or Spanish-speaking\n* Normal-Fetal-Weight Pregnancies Arm: Unstable housing or transportation\n* Normal-Fetal-Weight Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Multiple gestations\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Known fetal anomaly affecting biometric measurements\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal genetic disorder(s)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal infection(s)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-English or Spanish-speaking\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Unstable housing or transportation\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.","45 Years",{"count":59,"type":21},60,[24],"The goal of this proof-of-concept, case-control, clinical trial is to evaluate the efficacy of using two newer ultrasound technologies, quantitative ultrasound (QUS) and ultrafast power Doppler imaging (uPDI), to evaluate the health of the placenta, visualize blood flow through the placental vasculature by color Doppler imaging in singleton pregnancies with and without fetal growth restriction (FGR).\n\n* Our primary objective is to investigate the ability of using these ultrasound technologies to distinguish healthy pregnancies from those affected by FGR, a condition characterized by a fetal weight below the 10th percentile for the gestational age or abdominal circumference of the pregnancy.\n* Secondary aims include longitudinal evaluation of differences in QUS and uPDI imaging over gestation and changes in these measures with evolution of utero-placental insufficiency including with the development of abnormal umbilical-artery Doppler testing, diagnosis of severe FGR, identification of stillbirth, and detection of preeclampsia or preterm birth.\n\nInvestigators will compare QUS\u002FuPDI imaging and values in pregnancies determined to be healthy by approved, standard-of-care growth ultrasounds to those diagnosed with FGR.\n\nParticipants will receive research ultrasounds with the experimental Verasonics Vantage 256 system (Verasonics, Inc, Kirkland, WA) utilizing uPDI\u002FQUS every three weeks following their routine growth ultrasound evaluation until delivery. Demographic, obstetric, and delivery-related information, as well as portions of subjects' past medical history will be utilized by researchers to further contextualize imaging and variables gathered during the research ultrasounds.",[63,64,65,66,36,67,29,68],"Fetal Growth Restriction (FGR)","Placental Insufficiency","Preeclampsia","Still Births","Pregnancy Complications","Ultrasound",[70,71,72,73,74,68,36,67,75,76,77,78,79,80,81,65,82,83,84,85],"Fetal Growth Restriction","FGR","Placental Imaging","Utero-Placental Insufficiency","Growth Restriction","Maternal Fetal Medicine","Ultrafast Power Doppler Imaging","Quantitative Ultrasound","uPDI","QUS","MFM","Stillbirth","Verasonics","Verasonics Vantage 256","Carilion Clinic","Virginia Tech","RECRUITING","2026-05-20",{"date":89,"type":42},"2026-05-22",{"date":91,"type":42},"2025-04-23",{"date":93,"type":21},"2026-11",{"name":84,"class":49},1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":95},"100470268","mediterranean-diet-on-pregnancy-and-foetus-development-100470268","NCT05403632","Mediterranean Diet on Pregnancy and Foetus Development","Influence of Mediterranean Dietary Habits on Pregnancy and Foetus Development: the Role of Epigenetics and Inflammation","Inclusion Criteria:\n\n* pregnant women attending the Units of Obstetrics and Gynecology at Neuromed Clinical Research Network\n* women within the first trimester of pregnancy\n* women who express the willing to deliver at the aforementioned operating units\n\nExclusion Criteria:\n\n* pregnancy with foetuses with known chromosomal or congenital malformation\n* history of inflammatory disease\n* use of immunosuppressant drugs\n* pre-existing diabetes or hypertension\n* conception by heterologous artificial insemination\n* malabsorptive bariatric surgery\n* eating disorders","50 Years",{"count":105,"type":21},2000,"OBSERVATIONAL","The Mediterranean-style diet has been associated with longevity, long-life wellbeing, lower risk of cardiovascular disease, cancer, obesity, and metabolic syndrome. Research is pointing to the benefits that MeD could have in pregnant. Pregnancy is a very complex period and recently, the attention has been focused on the possibility that healthy dietary patterns positively influence pregnancy and the development of organs in the offspring. The mechanisms through which MeD influences pregnancy and fetal growth may partly depend on its antinflammatory properties and possibly on changes in epigenetic mechanisms. Systemic inflammation might contribute to the association between maternal obesity and less favorable neurodevelopmental outcomes. The investigators aim to define how maternal adhesion to MeD may affect pregnancy and new-born development, hence representing a notable burden from a public health and social perspective. Main objective of this project is to build up a birth cohort suitable to investigate the role of maternal dietary habits on maternal and new-born health, with special focus on MeD and its possible mechanism of action through epigenetic and inflammation changes. To establish a mother\u002Fnew-born cohort, collect detailed information on maternal dietary habits and set-up a biobank of biological samples to evaluate the association between dietary habits and pregnancy outcomes. The investigators will recruit 2000 pairs (mother, new-born) in different obstetrics departments. To investigate the association between maternal dietary habits, foetal growth and offspring development and possible mediation by the inflammation profile of the mother. To understand whether maternal dietary habits are associated with epigenetic changes in the offspring and if this process is driven by the inflammation profile of the mother. Venous blood samples will be obtained at the baseline and at each gestational period for ultrasound at 11-13 gestational weeks, 20-22 weeks and 30-32 weeks. Women will be followed-up with standard clinical and 2D ultrasound examinations at gestational weeks 11-13, 20-22 and 30-32 to evaluate the fetal growth. Offspring development will be assessed at 6, 12, 18, 24 months of age. After delivery, the investigators will collect umbilical cord blood and saliva samples from new-born using standard procedures. To understand if new-born epigenetics is associated with infant physical and neurocognitive development in the following 2 years.",[29,109,110],"Fetal Development","Infant Development","2026-04-08",{"date":113,"type":42},"2026-04-09",{"date":115,"type":42},"2023-05-01",{"date":117,"type":21},"2027-12-31",{"name":119,"class":49},"Neuromed IRCCS",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":95},"100621955","cheer-oral-health-in-pregnancy-study-100621955","NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study",{"count":129,"type":21},160,[24],"Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[133,134,36,29,135,136,137],"Gingivitis","Dental Health","Randomized Controlled Trial","Periodontal Disease","Gum Disease","2026-04-01",{"date":140,"type":42},"2026-04-07",{"date":142,"type":21},"2026-06-01",{"date":144,"type":21},"2028-06-01",{"name":146,"class":49},"University of California, San Francisco",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100609338","michigan-healthy-mom-mi-mom-pregnancy-improvement-web-application-trial-100609338","NCT07213284","Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial","Site Randomized Trial to Evaluate Behavioral Intervention Via Web-Based Application (MI MOM- Michigan Healthy Moms Application) to Improve Pregnancy Outcomes","MI-MOM App","Inclusion Criteria:\n\n* Pregnant at 20 weeks gestation or less\n* 18 years of age or older\n* Access to smartphone with text messaging and internet access\n* Speaks English\n* Enrolled in Medicaid for health insurance\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Not pregnant or pregnant with more than 20 weeks gestation\n* No access to a smartphone with text messaging and internet access\n* Not English speaking\n* Not enrolled in Medicaid for health insurance",{"count":156,"type":21},500,[24],"The purpose of this research study is to see if using the MI MOM App improves pregnancy and postpartum health. There are two study groups, where one group is \"treatment as usual\" and the other is the \"MI MOM App\" group. Both groups will be asked to answer questions about their pregnancy health. Researchers will also retrieve vital records and Medicaid claims information related to pregnancy for both groups. Those in the \"MI MOM App\" group will receive mobile web app content and text messages with informational links and links to videos and micro-interventions. They will also identify up to three close friends or family members who will be invited to receive text messages. Those in the \"MI MOM App\" will also have the option to contact a community health worker as needed.",[36,160,29],"Pregnancy, Complications",[36,162,163,164,165],"App","Behavioral Intervention","Web-based Application","Postpartum","2026-03-10",{"date":168,"type":42},"2026-03-12",{"date":138,"type":21},{"date":171,"type":21},"2031-12-31",{"name":173,"class":49},"Michigan State University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100556944","unravelling-the-interplay-of-weight-stigma-and-pregnancy-outcomes-a-prospective-cohort-study-100556944","NCT06531694","Unravelling the Interplay of Weight Stigma and Pregnancy Outcomes: A Prospective Cohort Study","Inclusion Criteria:\n\n* Pregnant between 10-22 weeks' gestation\n* Greater or equal than 18 years of age\n* Booked to give birth at Adelaide Women's and Children's Hospital or Royal Women's and Children's Brisbane\n* Access to the Internet to complete the survey\n* Consents to the extraction of hospital electronic medical record data about the woman and relevant to the study.\n* Ability to read and understand English\n\nExclusion Criteria:\n\n* Pregnant with multiple gestation\n* Insufficient English language skills to consent and complete the questionnaires.",{"count":181,"type":21},800,"The goal of this prospective cohort study is to investigate the contribution of stigma and discrimination due to body size to adverse pregnancy outcomes. We also aim to explore the role of psychological and social factors in this relationship. The specific objectives of this study are:\n\nObjective 1: Explore weight stigma as a mediator of the association between BMI ≥30 kg\u002Fm2 and adverse pregnancy outcomes.\n\nObjective 2: Explore confounding factors not previously considered such as weight cycling, trauma, eating disorders, and internalised weight bias as mediators in the relationship between obesity and adverse pregnancy outcomes.",[184,29,185],"Weight Stigma","Overweight and Obesity",[187,188],"Prenatal care","Healthcare","2026-02-01",{"date":191,"type":42},"2026-02-04",{"date":193,"type":21},"2026-06",{"date":195,"type":21},"2028-12",{"name":197,"class":49},"Monash University",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":205,"minAge":18,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":95},"100534092","peking-university-birth-cohort-in-weifang-pkubc-wf-100534092","NCT06234332","Peking University Birth Cohort in Weifang (PKUBC-WF)","Peking University Birth Cohort in Weifang","Inclusion Criteria:\n\n* Pregnant woman\n\n  1. Pregnant women, 6-13\\^+6 gestational weeks\n  2. Resided in Weifang in the past half years and have no plan to move out after delivery\n  3. Pregnant women who plan to have antenatal care and delivery in Weifang maternal\\&Child Hospital.\n  4. Pregnant women who is willing to participate in this study with informed consent\n* Pregnant woman's husband\n\n  1. His wife was eligible for enrollment\n  2. He is the biological father of the child (his wife's current pregnancy)\n  3. Pregnant women's husband who is willing to participate in this study with informed consent\n* Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study.\n\n  5\\. Before the age of 8 years, his\u002Fher mother provided written informed consent. 6. After 8 years old, he\u002Fshe agreed to continue this study and signed the informed consent.\n\nExclusion Criteria:\n\n* Participants who cannot communicate normally.","ALL",{"count":207,"type":21},2800,"The PKUBC-WF is a prospective cohort study carried out in Weifang city of Shandong, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.",[210,29,211,212,213,214,215,216,217],"Health Problems in Pregnancy","Gestational Diabetes","Gestational Hypertension","Preterm Birth","Obesity","Mother-Infant Interaction","Child Development","Anemia","2025-11-18",{"date":220,"type":42},"2025-11-24",{"date":222,"type":42},"2024-02-01",{"date":224,"type":21},"2043-12-31",{"name":226,"class":49},"Peking University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":4},"100599953","a-culturally-adapted-digital-intervention-to-promote-maternal-care-utilization-using-multifaceted-approaches-100599953","NCT07091188","A Culturally Adapted Digital Intervention to Promote Maternal Care Utilization Using Multifaceted Approaches","A Culturally Adapted Digital Intervention to Promote Maternal Care Utilization Using Multifaceted Approaches (CALCIUM) Among an Ethnic Minority Community in China","Inclusion Criteria:\n\n* Pregnant women\n\nExclusion Criteria:\n\n* Not pregnant women",{"count":235,"type":21},1920,[24],"Maternal healthcare utilization is crucial for reducing maternal mortality, yet remains low in many underserved regions. The CALCIUM intervention, a culturally tailored, digital platform-integrated intervention, was developed to promote antenatal care (ANC) and institutional deliveries in Liangshan Yi Autonomous Prefecture, an ethnic minority community in China. The CALCIUM intervention was developed to address barriers including limited healthcare awareness, traditional norms and low-quality services. This intervention will evaluate the effectiveness, and cost-effectiveness of improving maternal healthcare utilization and pregnancy outcomes in an ethnic minority community.",[239,67,29],"Antenatal Care",[241,242,243,244],"antenatal care","ethnic minority","digital health","health education","2025-07-25",{"date":247,"type":42},"2025-07-29",{"date":249,"type":21},"2025-09",{"date":251,"type":21},"2027-06",{"name":253,"class":49},"Jiayao Xu",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":16,"sex":205,"minAge":261,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":95},"100451117","antenatal-and-postnatal-care-research-collective---household-survey-arch-100451117","NCT05154331","Antenatal and Postnatal Care Research Collective - Household Survey (ARCH)","ARCH","We will initially obtain verbal consent from the head of household (HoH), defined as an available adult (\\> 18 years old) who is able to provide information about household composition for pre-screening purposes. We will then identify potentially eligible women of reproductive age within each household and invite them to complete study screening procedures.\n\nWomen of reproductive age eligibility criteria\n\nInclusion criteria:\n\n* Verbal consent obtained from head-of-household\n* 15-49 years of age and a member of household in the catchment area\n* Willing and able to provide written informed consent or assent with next-of-kin consent\n* Willing to undergo study procedures\n\nExclusion criteria:\n\nAny other condition (social or medical) that, in the opinion of the study staff, would make participation unsafe or complicate data interpretation. Study staff may note physical, psychological, or social conditions not explicitly stated in the eligibility criteria that could make some women poor candidates for study participation.","1 Day","49 Years",{"count":264,"type":21},7500,"The overarching goal of the ARCH Survey is to establish a prospective longitudinal pregnancy surveillance study in Lusaka, Zambia, to precisely characterize the pregnancy rate and outcomes of women of reproductive age prior to, during, and following pregnancy and to investigate the structural, sociodemographic, and clinical covariates that contribute to adverse outcomes in each reproductive epoch.",[267,29],"Maternal Health",[269],"pregnancy health","2025-05-23",{"date":272,"type":42},"2025-05-30",{"date":274,"type":42},"2022-03-29",{"date":142,"type":21},{"name":277,"class":49},"University of North Carolina, Chapel Hill",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":16,"sex":205,"minAge":4,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":95},"100587267","human-genes-and-microbiota-in-early-life-100587267","NCT06926166","Human Genes and Microbiota in Early Life","Human Genes and Microbiota in Early Life (HuGME)","HuGME","Inclusion Criteria:\n\nPregnant women with \\\u003C 20 weeks of gestation Pregnant women intended to eventually deliver in Guangzhou Women and Children's medical center Permanent residengts of families intended to remain in Guangzhou with their child for ≥3 years\n\nExclusion Criteria:\n\nRefuses to have blood and stool samples stored at Born in Guangzhou cohort study Biobank.",{"count":287,"type":21},20000,"The long-term goal of the Human Genes and Microbiota in Early Life (HuGME) is to explore the short- and long-term effects of maternal microbiota during pregnancy and the microbiota colonization of their offspring early in life and their interaction with the host on maternal-offspring health consequences in later life in the born in Guangzhou cohort study in China. Identification of the effect of microbiota in early life, as well as environmental factors and microbe-host interaction, will lead to a better understanding of disease pathogenesis and provide a foundation for targeted mechanistic investigation into the consequences of microbial-host crosstalk for long-term health. It also can result in new strategies to predict and prevent diseases in later life.",[290,29,67,291,292,293,294],"Host and Microbiome","Neurodevelopmental Disorders","Immune Development","Childhood Obesity","Type 2 Diabetes","2025-04-07",{"date":297,"type":42},"2025-04-13",{"date":299,"type":42},"2019-04-01",{"date":301,"type":21},"2038-12-31",{"name":303,"class":49},"Guangzhou Women and Children's Medical Center",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100477967","born-in-guangzhou-intervention-study-100477967","NCT05503849","Born In Guangzhou Intervention Study","BIGIS","Inclusion Criteria:\n\n* Pregnant women attending prenatal care at Guangzhou Women and Children's Medical Center (GWCMC) \\\u003C20 weeks' gestation\n* Pregnant women plan to deliver at GWCMC\n* Pregnant women intend to reside in Guangzhou for at least 3 years\n\nExclusion Criteria:\n\n* Multiple pregnancies\n* Existing medical conditions (uncontrolled diabetes, hypertension or thyroid disease; other serious cardiovascular diseases, respiratory or systematic disorders)\n* Use of drugs (aspirin, metformin, low molecular weight heparin)\n* Women with reading and\u002For writing difficulties\n* Women with serious mental disorders\n* Women with eating disorders",{"count":312,"type":21},1160,[24],"The main objective of this study is to test the efficacy of an intervention package (dietary, physical and lifestyle modification) during pregnancy in improving the clinical outcomes of mother-infant dyads.",[29,216,67],{"date":317,"type":42},"2025-04-10",{"date":319,"type":42},"2024-07-22",{"date":321,"type":21},"2032-09",{"name":303,"class":49},2,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":335,"conditions":336,"keywords":342,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":355,"locationsCount":323},"100554812","impact-of-uterine-immune-profiling-and-personalized-treatments-in-patients-receiving-a-single-blastocyst-a-matched-controlled-study-100554812","NCT06503952","Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst: a Matched Controlled Study","Impact of Uterine Immune Profiling and Personalized Treatments on Subsequent Live Birth in Patients Receiving a Single Blastocyst: a Matched Controlled Study","UTIMPROSET","For case: Uterine immune profiling followed by a Day-5 fresh SET or day-5 or Day-6 freeze-thawed SET within the nine months following the uterine immune profiling between January 2020 and June 2023.\n\nWill be excluded patients with no SET day-5, with uterine immune profiling more than nine months before, or with no matching pair For control: Blastocyst SET without uterine immune profiling within the year prior the embryo transfer matched to the case group between January 2018 on June 2023\n\n* maternal age (+\u002F-1 year) and\n* the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and\n* the same type of transfer (IVF, ICSI, frozen transfer) and\n* the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).","41 Years",{"count":334,"type":21},340,"A recent randomised controlled trial and previous large cohort studies have shown that the uterine immune environment is a crucial element in improving the performance of Assisted Reproductive therapy (ART). As previous studies mixed Day-3, Day-5, single or doble embryo transfer, the clear influence of the endometrial environment on the embryo itself and its type of transfer (fresh or freeze thawed) need further investigation.\n\nTo complement previous studies, the present matched- pair study aims to select the population who exclusively received a single Day-5 embryo transfer (SET) and benefitted of a uterine immune profiling between 1 January 2020 and 30 June 2023 before the SET Day-5.\n\nThis population will be matched to a population. who did not have uterine immune profiling in the nine months prior to the single Day 5 embryo transfer between 2018 and 2023.\n\nThe matching criteria are the maternal age (+\u002F-1 year), the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and the same type of transfer (IVF, ICSI, frozen transfer) and the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).\n\nThe primary end-point is the live birth rate (LBR) following the Day 5 SET in the population who benefited from pre-SET immune profiling versus the LBR following the Day 5 SET in the pair- matched population who did not benefit from pre-SET uterine immune profiling Secondary end point are the clinical pregnancy rate and miscarriage rate per SET in the two paired populations",[337,338,339,29,340,341],"Infertility","Success Rate of Assisted Reproductive Therapy","Single Embryo Transfer","Immunological Tolerance","Immune System",[343,344,345,346,347,348],"infertility","success rate of assisted reproductibve therapy","Single embryo transfer","uterine immune profiling","personalized care","Live birth rate","2024-12-20",{"date":351,"type":42},"2024-12-27",{"date":353,"type":21},"2025-01-15",{"date":272,"type":21},{"name":356,"class":49},"Matricelab Innove",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100570955","comparison-of-pregnancy-outcomes-in-women-with-polycystic-ovarian-syndrome-with-and-without-glucophage-100570955","NCT06713967","Comparison of Pregnancy Outcomes in Women with Polycystic Ovarian Syndrome with and Without Glucophage","Comparison of Outcome of Pregnant Females with Polycystic Ovarian Syndrome with or Without Glucophage","Inclusion Criteria:\n\nPregnant females aged 18-40 years Diagnosed with polycystic ovarian syndrome (PCOS) before conception, as per operational definition.\n\nPresent in the 1st trimester at the booking visit. Singleton fetus on booking scan between 5th to 13th week of gestation.\n\nExclusion Criteria:\n\nFemales who do not give informed consent for follow-up. Females with preeclampsia (BP ≥140\u002F90 mmHg with proteinuria \\>+1 on dipstick method).\n\nFemales already diagnosed with gestational diabetes (OGTT \\>186 mg\u002Fdl). Females already taking trial treatment (as per medical record). Twin pregnancy or abnormal placenta (assessed on ultrasound). Diagnosed hypertensives and diabetic patients.","40 Years",{"count":366,"type":21},70,[24],"The goal of this clinical trial is to learn if Glucophage (metformin) improves pregnancy outcomes in women with polycystic ovarian syndrome (PCOS). It will also evaluate the safety of Glucophage during pregnancy. The main questions it aims to answer are:\n\nDoes Glucophage reduce the risks of early pregnancy loss, preterm delivery, and gestational diabetes? Are there any medical problems associated with taking Glucophage during pregnancy? Researchers will compare Glucophage with standard care (diet and exercise) to see if it improves pregnancy outcomes in women with PCOS.\n\nParticipants will:\n\nTake Glucophage or follow a standard diet and exercise plan throughout pregnancy.\n\nAttend regular follow-up visits for checkups, ultrasounds, and blood tests. Have their pregnancy outcomes, such as fetal growth and gestational diabetes, recorded.",[370,29],"Polycystic Ovarian Syndrome (PCOS)","2024-12-03",{"date":373,"type":42},"2024-12-06",{"date":375,"type":21},"2025-02-02",{"date":377,"type":21},"2025-05-26",{"name":379,"class":49},"University of Health Sciences Lahore",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":388,"enrollmentInfo":389,"targetDuration":261,"studyType":106,"phases":4,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":95},"100570651","study-on-fertility-parameters-in-women-with-germline-variants-in-brca1-and-brca2-100570651","NCT06710015","Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2","B.Fert: Retrospective and Prospective Observational Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2","BFert","BRCA1 and BRCA2 carriers\n\nInclusion Criteria:\n\n* age \\> 18 years\n* presence of a pathogenic variant in the BRCA genes\n* signed informed consent Exclusion Criteria\n* presence of a pathogenic variant in another gene (not BRCA)\n* significant psychiatric or clinical impairment affecting the ability to consent to the study\n\nControl cohort\n\nInclusion Criteria:\n\n\\- Relatives up to the third degree of the first cohort who tested negative on predictive testing for the familial pathogenic variant in the BRCA genes, matched for age where possible.\n\nExclusion Criteria:\n\n* absence of a pathogenic variant in another gene (non-BRCA) found in a family member\n* significant psychiatric or clinical impairment affecting the ability to consent to the study","100 Years",{"count":390,"type":21},128,"Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased risk of developing breast and ovarian cancers. According to current guidelines from the National Comprehensive Cancer Network, the risk of developing breast cancer exceeds 60% for both genes, while the risk for ovarian cancer ranges from 39% to 58% for the BRCA1 and from 13% to 29% for the BRCA2. The detection of a pathogenic variant in the BRCA1 or BRCA2 genes necessitates both the establishment of appropriate primary and secondary surveillance measures for carriers and the discussion of the familial implications of such findings.\n\nThe molecular basis initially suggesting a possible association between germline variants in BRCA1 and BRCA2 genes and diminished ovarian reserve lies in the cellular impact of impaired or defective repair of DNA double-strand breaks (DSBs) on oocytes. Notably, BRCA1 and BRCA2 genes play a key role in the ATM-related mechanism for DSB repair through the homologous recombination (HR) pathway.\n\nAlthough preclinical evidence supports a potential correlation between defective DSB repair and normal follicle maturation processes, clinical studies on large cohorts of patients with pathogenic BRCA1 and BRCA2 variants yield inconsistent results. This discrepancy is likely attributable to the inherent challenges in recruiting a sufficiently homogeneous and statistically significant sample size.\n\nThe aim of the study is to evaluate reproductive capacity in women carrying pathogenic variants in the BRCA1\u002F2 genes by assessing the number of pregnancies during the period from January 1, 2018, to December 31, 2023. Secondary objectives include evaluating menopausal characteristics and pregnancy outcomes.",[393,394,395,396,29],"BRCA1 and\u002For BRCA2 Variant Carriers","Fertility","Reproductive Age","Menopause","2024-11-26",{"date":399,"type":42},"2024-11-29",{"date":401,"type":21},"2024-12-01",{"date":142,"type":21},{"name":404,"class":49},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":95},"100566340","phase-4-levothyroxine-intervention-in-pregnant-women-with-tsh-25-miul-upper-limit-of-reference-range-and-negative-thyroid-peroxidase-antibody-100566340","NCT06653907","Levothyroxine Intervention in Pregnant Women with TSH （2.5 MIU\u002FL-upper Limit of Reference Range） and Negative Thyroid Peroxidase Antibody","Randomized Control Study of Levothyroxine Intervention in Pregnant Women with Thyroid Stimulating Hormone Between 2.5 MIU\u002FL and Upper Limit of Reference Range and Negative Thyroid Peroxidase Antibody","LIGHT","Inclusion Criteria:\n\n1. Women of childbearing age（18-45 years old）, natural pregnancy, singleton pregnancy.\n2. Measure thyroid related indexes within 8 weeks of pregnancy: TSH 2.5mIU\u002FL-ULRR, FT4 is normal and TPOAb negativity.\n3. Willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of recurrent miscarriage (≥3 times).\n2. Assisted reproduction (artificial insemination, in vitro fertilization and embryo transfer);\n3. Suffer from diseases that seriously affect pregnancy outcome, including hypertension, diabetes, heart disease, liver and kidney dysfunction, etc.\n4. Failure of vital organs.\n5. Except autoimmune thyroid disease，suffer from other autoimmune diseases.\n6. Thyroid diseases (including hyperthyroidism, thyroid cancer, thyroid amyloidosis and other extensive intrathyroidal diseases, current subacute thyroiditis, iodine-deficiency endemic goiter, thyroidectomy or 131I treatment, previous thyroid Ultrasound prompts diffuse thyroid disease, etc.).\n7. Use of thyroid-related drugs (lithium carbonate, thioureas, sulfonamides, sodium para-amino salicylate, potassium perchlorate, phenylbutazone, sulfate, tyrosine kinase inhibitor, etc.) during screening and affect thyroid Functional testing drugs. (Including glucocorticoids, metoclopramide, propranolol, amiodarone, sodium valproate, etc.)\n8. Secondary hypothyroidism or central hypothyroidism. (Including pituitary tumors, surgery, radiotherapy, lymphocytic hypophysitis, etc.)\n9. L-T4 allergy.\n10. Unwilling to sign an informed consent.\n11. Other clinicians judged that they are not suitable to participate in the study.",{"count":414,"type":21},400,[416],"PHASE4","The goal of this clinical trial is to learn if levothyroxine (L-T4) works to treat pregnant women with TSH 2.5 mIU\u002FL-the upper limit of reference range (ULRR) of pregnancy and TPOAb-negative. It will also learn about the safety of L-T4. The main quesitons the investigator want to answer are:\n\n* Will L-T4 reduce miscarriage rates and have an impact on pregnancy complications in pregnant participants?\n* What medical issues do participants have when taking L-T4 during pregnancy? -Investigators will compare L-T4 with placebo (a substance with a similar appearance without medication) to see if L-T4 could reduce miscarriage rates\n\nParticipants should:\n\n* Take L-T4 or placebo during the whole pregnancy.\n* Visit the hospital once every 6-8 weeks during pregnancy for checkups and tests\n* Keep a diary of their pregncny complications and daily record of L-T4 or placebo intake.\n* Visit the hospital for examination 42 days postpartum for checkups and follow up by phone at 6 and 12 months postpartum.",[419,420,29],"Thyroid Abnormalities","Pregnant Woman",[422,423,424,425,426],"TSH","TPOAb","pregnant women","levothyroxine","outcome","2024-10-21",{"date":429,"type":42},"2024-10-23",{"date":431,"type":21},"2024-10-25",{"date":433,"type":21},"2027-10-31",{"name":435,"class":49},"Yang ZHANG",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":16,"sex":205,"minAge":4,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":95},"100249529","the-born-in-guangzhou-cohort-study-bigcs-100249529","NCT02526901","The Born in Guangzhou Cohort Study (BIGCS)","BIGCS","Inclusion Criteria:\n\n* Pregnant women with \\\u003C20 weeks of gestation\n* Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n* Permanent residents or families intended to remain in Guangzhou with their child for ≥3 years",{"count":444,"type":21},30000,"The Born in Guangzhou Cohort Study (BIGCS) was established to investigate the short- and long-term effects of exposure in early life on health consequences in Guangzhou, China. Data are collected regarding environmental, occupational and lifestyle exposures as well as health outcomes in later life. Biological samples including blood and tissue samples are also collected from the participants.",[447,29,448,292,293,290],"Intrauterine Hyperglycemia","Neurodevelopment","2024-02-22",{"date":451,"type":42},"2024-02-26",{"date":453,"type":4},"2012-02-01",{"date":455,"type":21},"2030-12-31",{"name":303,"class":49}]